Linguamatics Extends License to its Agile Text Mining Platform for AstraZeneca
(09 July 2009, Cambridge, UK) — Linguamatics, a leader in enterprise text mining for the life science and other markets, today announced that AstraZeneca, a customer of Linguamatics since 2003, has extended its license to the I2E semantic knowledge-discovery platform with a further multi-year deal. I2E provides flexible and scalable enterprise text mining within AstraZeneca’s knowledge engineering strategy, and supports decision making at many points in the drug discovery process, including target selection, biomarker discovery and safety/toxicology. Financial details of the agreement were not disclosed.
“AstraZeneca’s researchers need efficient access to relevant biomedical knowledge,” commented Roger Hale, COO and Co-founder of Linguamatics. “I2E uses agile NLP-based text mining technology to provide high quality insights from literature sources in real-time, supporting key decisions with the right information at the right time.”
“The early prediction of candidate drug efficacy and safety is paramount in any successful drug discovery campaign,” said Ian Dix, Knowledge Engineering Capability Lead, Discovery Information, AstraZeneca. “I2E is being used for knowledge discovery to support better-informed scientific decision-making, impacting discovery performance and competitiveness.”
ABOUT LINGUAMATICS
Linguamatics helps organizations to maximize the value derived from information resources through effective deployment of innovative natural language processing (NLP) based technology. The versatile interactive information extraction system, I2E, helps organizations to do much more than simply cope with vast quantities of information. Its unique combination of search and text mining helps organizations to turn this information into a competitive advantage. From life sciences and healthcare to business intelligence, from media analysis to security, users mine large collections of documents, extracting relevant facts,relationships and quantitative data from content such as scientific papers, news feeds, patents, or internal reports. Linguamatics has a rapidly growing user community with I2E deployed at most top-10 pharma companies. The company was founded in 2001, and is based in Cambridge, UK.
ABOUT I2E
Linguamatics’ flagship I2E technology combines four key capabilities to enable users to rapidly extract relevant facts and relationships from large document collections:
– Natural language processing (NLP): using linguistics to quickly interpret the meaning of unstructured text sources.
– Search engine approach: where users can define and refine ad hoc queries interactively, returning results in real time.
– Intuitive reporting: presenting extracted information with drill-down to supporting evidence.
– Domain knowledge plug-in: providing enhanced semantic search capabilities using domain knowledge such as taxonomies, thesauri and ontologies.
I2E features a client-server architecture built using industry-standard Java and C for use by single users, project teams, or in enterprise-wide deployments. Organizations have full control over source content to be mined, definition of queries and results output.
For further information on Linguamatics products and solutions, visit www.linguamatics.com.
ABOUT ASTRAZENECA
AstraZeneca is a major international healthcare business engaged inresearch, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world’s leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information visit: www.astrazeneca.com.
The Linguamatics logo is a trademark of Linguamatics Ltd. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.
